Click here for Xalkori® (crizotinib) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
On 31 May 2018, the National Institute for Health and Care Excellence (NICE) issued their Final Appraisal Determination (FAD) on the use of XALKORI for the treatment of ROS1-positive advanced non-small cell lung cancer (NSCLC).1
For further information on patient eligibility please refer to the Xalkori CDF MAA.4
*Blueteq is an online approval system for the management and approval of high-cost drugs, as per the agreed criteria from NHSE. The Blueteq CDF request system provides a specific form for each CDF therapy (www.blueteq.com/CDF) and an instant approval will be given, provided the form is completed correctly.
On 11 June 2018, the Scottish Medicines Consortium (SMC) issued their advice on the use of XALKORI for the treatment of adults with ROS1-positive advanced NSCLC.
XALKORI is now available across Scotland on the NHS for adults with ROS1-positive advanced NSCLC.
XALKORI as a monotherapy is indicated for:3
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. March 2021
Sign up now
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020